Evidence map›Paper›PMID 36387062›Full record

ArticleJAAD international2023

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.

Angela L Bosma, Wouter Ouwerkerk, Madeline J Heidema, David Prieto-Merino, Michael R Ardern-Jones, Paula Beattie, Sara J Brown, John R Ingram, Alan D Irvine, Graham Ogg and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Angela L BosmaDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
Wouter OuwerkerkDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
Madeline J HeidemaDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
David Prieto-MerinoFaculty of Medicine, Universidad de Alcalá, Madrid, Spain.
Michael R Ardern-JonesClinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Paula BeattieDepartment of Dermatology, Royal Hospital for Children NHS Trust, Glasgow, UK.
Sara J BrownCentre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK.
John R IngramDepartment of Dermatology, Division of Infection & Immunity, Cardiff University, Cardiff, UK.
Alan D IrvineDepartment of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
Graham OggMRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Prakash PatelUnit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, UK.
Nick J ReynoldsDepartment of Dermatology, Institute of Cellular Medicine, Medical School, Newcastle University, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
R M Ross HearnDepartment of Dermatology & Photobiology, Ninewells Hospital and Medical School, Dundee, UK.
Mandy WanPharmacy Department, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Richard B WarrenDermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical 17 Research Centre, University of Manchester, Manchester, UK.
Richard T WoolfSt John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Ariënna M HyseniDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
Louise A A GerbensDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
Phyllis I SpulsDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
Carsten FlohrUnit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King's College London, London, UK.
Maritza A Middelkamp-HupDepartment of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
TREAT NL registry and UK-Irish A-STAR Study Groups

Funding

Medical Research Council MC_UU_00008/5Medical Research Council MC_UU_00036/2
6 · The paper itself

Abstract

Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.

Indexed as

AD, atopic dermatitisAE, adverse eventatopic dermatitisatopic eczemaciclosporindaily practiceDLQI, Dermatology Life Quality IndexDST, Dark Skin Type(s)dupilumabEASI, Eczema Area and Severity IndexeffectivenessethnicityIQR, interquartile rangeLST, Light Skin Type(s)methotrexatemorphologyNRS, Numerical Rating ScalePOEM, Patient-Oriented Eczema Measureraceregistryroutine clinical caresafetySD, Standard Deviationskin typesystemic treatment

Identifiers

PMID36387062
PMCPMC9661502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.